arrow
J

Joe Wei

scientia clinical research
H指数:9
被引数:234

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER

早期肿瘤学临床试验中健康相关生活质量的预期性评估:PEARLER

2025-12-010
OAAI
PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading

PATH-18. 研究CDKN2A缺失在IDH突变型胶质瘤中的作用:超越肿瘤分级的生物学见解

2025-11-110
OA
INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma

INTERROGATE-GBM Ⅰ期临床试验:针对巨细胞病毒(CMV)抗原的胶质母细胞瘤免疫治疗肽疫苗

2025-11-010
OAAI
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours

疫苗诱导的免疫在胶质瘤患者中维持,与其他实体瘤相比。

2025-10-150
OA
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
2025-01-010
PRE
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

澳大利亚老年不可切除的III期非小细胞肺癌患者放化疗后巩固durvalumab的真实世界疗效和毒性

2024-03-015
OA
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
2024-02-074
OAAI
Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Anti-PD-1单克隆抗体 (mab) 联合化疗一线治疗转移性非小细胞肺癌 (mNSCLC) 优于Anti-PD-L1单克隆抗体: 一项网状Meta分析

2023-06-262
OAAI